Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H23ClFN5O3 |
Molecular Weight | 459.901 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(C=C1OC(=O)N3CCN(C)C[C@H]3C)C(NC4=CC=CC(Cl)=C4F)=NC=N2
InChI
InChIKey=MXDSJQHFFDGFDK-CYBMUJFWSA-N
InChI=1S/C22H23ClFN5O3/c1-13-11-28(2)7-8-29(13)22(30)32-19-9-14-17(10-18(19)31-3)25-12-26-21(14)27-16-6-4-5-15(23)20(16)24/h4-6,9-10,12-13H,7-8,11H2,1-3H3,(H,25,26,27)/t13-/m1/s1
Molecular Formula | C22H23ClFN5O3 |
Molecular Weight | 459.901 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
AZD-3759 is an oral inhibitor of both wild-type and mutant EGFR with IC50 values in nanomolar range. The drug was discovered by AstraZeneca for the treatment of non-small-cell lung cancer with CNS metastases. AZD-3759 can penetrate the blood-brain barrier and was confirmed to be effective in vitro with NSCLC cell lines as well as in mouse model of brain metastases. AZD-3759 is currently in Phase 1 clinical trial.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363049 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29430654 |
102.0 nM [IC50] | ||
Target ID: P00533|||Q9GZX1 Gene ID: 1956.0 Gene Symbol: EGFR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26313252 |
0.28 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator​
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
yes [IC50 1.7 uM] | ||||
yes [IC50 15 uM] | ||||
yes [IC50 18.5 uM] | ||||
yes [IC50 19.3 uM] | ||||
yes [IC50 24.7 uM] | ||||
yes [IC50 8.17 uM] | ||||
yes [IC50 8.8 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. | 2015 Oct 22 |
|
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. | 2016 Dec 7 |
|
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. | 2016 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02228369
AZD-3759 is given at a dose of 50 mg, administered twice daily, or 160 mag, administered once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26313252
100 uL of NCI-H3255 (EGFR L858R), NCI-H838 (EGFR wild type) and PC-9 (Exon 19 deletion EGFR) cells were seeded in 96 well cell culture plates and incubated at 37C with 5% CO2
overnight and then treated with AZD-3759 at concentrations ranging from 10 to 0.0003 mM. IC50s for cellular inhibition of EGFR phosphorylation were 7.2, 64.5, 7.7 nM, respectively. In cellular proliferation assay, the cells were exposed to concentrations of compounds ranging from 30 to 0.0003 mM for 72 hours. GI50 values were 7, 21556 and 7.7 nM, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:19:44 GMT 2023
by
admin
on
Sat Dec 16 11:19:44 GMT 2023
|
Record UNII |
67SX9H68W2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB14795
Created by
admin on Sat Dec 16 11:19:44 GMT 2023 , Edited by admin on Sat Dec 16 11:19:44 GMT 2023
|
PRIMARY | |||
|
67SX9H68W2
Created by
admin on Sat Dec 16 11:19:44 GMT 2023 , Edited by admin on Sat Dec 16 11:19:44 GMT 2023
|
PRIMARY | |||
|
300000010813
Created by
admin on Sat Dec 16 11:19:44 GMT 2023 , Edited by admin on Sat Dec 16 11:19:44 GMT 2023
|
PRIMARY | |||
|
11144
Created by
admin on Sat Dec 16 11:19:44 GMT 2023 , Edited by admin on Sat Dec 16 11:19:44 GMT 2023
|
PRIMARY | |||
|
C118289
Created by
admin on Sat Dec 16 11:19:44 GMT 2023 , Edited by admin on Sat Dec 16 11:19:44 GMT 2023
|
PRIMARY | |||
|
78209992
Created by
admin on Sat Dec 16 11:19:44 GMT 2023 , Edited by admin on Sat Dec 16 11:19:44 GMT 2023
|
PRIMARY | |||
|
1626387-80-1
Created by
admin on Sat Dec 16 11:19:44 GMT 2023 , Edited by admin on Sat Dec 16 11:19:44 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
CSF/PLASMA RATIO | BIOLOGICAL |
|
SPECIES BIOLOGICAL |
|
||